AlzChem Group Z Score vs. Revenue

ACT Stock  EUR 57.00  1.20  2.06%   
Considering AlzChem Group's profitability and operating efficiency indicators, AlzChem Group AG may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess AlzChem Group's ability to earn profits and add value for shareholders.
For AlzChem Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AlzChem Group to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AlzChem Group AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AlzChem Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AlzChem Group AG over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between AlzChem Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if AlzChem Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AlzChem Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

AlzChem Group AG Revenue vs. Z Score Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining AlzChem Group's current stock value. Our valuation model uses many indicators to compare AlzChem Group value to that of its competitors to determine the firm's financial worth.
AlzChem Group AG is rated below average in z score category among its peers. It also is rated below average in revenue category among its peers totaling about  422,293,000  of Revenue per Z Score. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AlzChem Group's earnings, one of the primary drivers of an investment's value.

AlzChem Revenue vs. Z Score

Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

AlzChem Group

Z Score

 = 

Sum Of

5 Factors

 = 
1.0
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

AlzChem Group

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
422.29 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

AlzChem Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on AlzChem Group. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of AlzChem Group position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the AlzChem Group's important profitability drivers and their relationship over time.

Use AlzChem Group in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AlzChem Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AlzChem Group will appreciate offsetting losses from the drop in the long position's value.

AlzChem Group Pair Trading

AlzChem Group AG Pair Trading Analysis

The ability to find closely correlated positions to AlzChem Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AlzChem Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AlzChem Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AlzChem Group AG to buy it.
The correlation of AlzChem Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AlzChem Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AlzChem Group AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AlzChem Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your AlzChem Group position

In addition to having AlzChem Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in AlzChem Stock

To fully project AlzChem Group's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of AlzChem Group AG at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include AlzChem Group's income statement, its balance sheet, and the statement of cash flows.
Potential AlzChem Group investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although AlzChem Group investors may work on each financial statement separately, they are all related. The changes in AlzChem Group's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AlzChem Group's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.